NCT ID | NCT03685331 |
Title | Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer |
Recruitment | Not yet recruiting |
Gender | female |
Phase | Phase I |
Variant Requirements | yes |
Sponsors | Abramson Cancer Center of the University of Pennsylvania |
Indications | |
Therapies | |
Age Groups: | senior adult |